The table below shows Denali Therapeutics Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$131.20M
-$131.47M
-$113.62M
-$58.80M
-$72.11M
-$50.24M
Capital expenditure
$2.47M
$5.08M
$2.15M
$2.79M
$4.04M
$2.80M
Investing cash flow
$94.46M
$18.75M
-$453.19M
-$92.72M
-$117.88M
-$25.41M
Dividends paid
-
-
-
DNLI operating cash flow (10-K history)
Denali Therapeutics Inc. reported operating cash flow of -$412.60M for fiscal year 2025. That is down 18.7% from -$347.69M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$71.91M (FY 2016) to -$412.60M. Figures come from the company's audited annual reports as filed with the SEC.